Compare FND & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | HALO |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 8.8B |
| IPO Year | 2014 | 2001 |
| Metric | FND | HALO |
|---|---|---|
| Price | $53.22 | $67.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $77.25 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | 1.92 | ★ 2.56 |
| Revenue | ★ $4,684,088,000.00 | $151,862,000.00 |
| Revenue This Year | $7.56 | $28.24 |
| Revenue Next Year | $7.78 | $12.79 |
| P/E Ratio | ★ $26.09 | $26.18 |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $46.47 | $47.50 |
| 52 Week High | $92.41 | $82.22 |
| Indicator | FND | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 55.32 |
| Support Level | $46.47 | $67.02 |
| Resistance Level | $64.23 | $68.00 |
| Average True Range (ATR) | 2.57 | 1.70 |
| MACD | 0.81 | 0.79 |
| Stochastic Oscillator | 87.19 | 85.80 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.